Abstract
Background The infectious respiratory disease COVID-19, caused novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reached pandemic status during 2020. The primary statistic data are important to survey the actual circumstances of COVID-19. Here, we report the analysis of the primary data of COVID-19 in Japan during 2020.
Methods Data were collected and released systematically under Japan domestic law. Machine learning was conducted to estimate the positive rate in Japan and four prefectures (Tokyo, Osaka, Chiba, and Fukuoka).
Results Primary data analysis revealed there were at least two peaks of infection in Japan; the first one was during April 2020 and the second one started from November 1, 2020. Estimating the positive rate in Japan as well as in the four prefectures reinforced the above observations. The positive rate in Japan during 2020 was estimated to be around 6% to 8%. We also estimated that 1.95 million people were possibly exposed to the novel virus on October 31, 2020. The numbers of related deaths were over 3,000 people at the end of 2020.
Conclusion We estimated the infection rate of SARS-CoV-2 in Japan to be 6–8% in 2020. We also concluded that Japan had at least two infection-spreading periods, the first one being from Jan 19, 2020 until May 2020, and the second one beginning from November 1, 2020. Importantly, our analysis supports the need for clear definition of the criteria for conducting confirmation tests before embarking on data analysis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author receives no financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data are obtained by governments open data archive per admission of each government's open data policy.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are obtained by governments open data archive. Because all data used in this study are written in Japanese, the original data are listed in main text and/or supplemental data